Drug General Information (ID: DDIGR25LB6)
Drug Name			Cyclosporine		Drug Info		Orlistat		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiviral Agents				Antiobesity Agents
Structure

Mechanism of Cyclosporine-Orlistat Interaction (Severity Level: Major)
Altered Fat-soluble drugs absorption Click to Show/Hide Mechanism Graph
Drug Name		Cyclosporine				Orlistat
Mechanism		Fat-soluble agent				Decrease fat-soluble agent absorption
Key Mechanism Factor 1
		Factor Name		Pharmacokinetic
		Factor Description		Alters the absorption of the drug, leading to changes in the plasma concentration of the drug and affecting the pharmacological effects.
Mechanism Description		Decreased absorption of Cyclosporine caused by Orlistat

Recommended Action
Management		Given the risk of organ rejection associated with inadequate drug levels, orlistat should preferably not be used in transplant patients treated with cyclosporine. If concomitant therapy is necessary, separating the doses by at least 2 hours may help minimize the potential for an interaction. Cyclosporine blood levels should be closely monitored and patients should be monitored for signs of rejection.

References
1	Colman E, Fossler M "Reduction in blood cyclosporine concentrations by orlistat." N Engl J Med 342 (2000): 1141. [PMID: 10766596]
2	Nagele H, Petersen B, Bonacker U, Rodiger W "Effect of orlistat on blood cyclosporin concentration in an obese heart transplant patient." Eur J Clin Pharmacol 55 (1999): 667-9. [PMID: 10638396]